APA (7th ed.) Citation

A, G., Y, D., RR, V., MF, H., KE, T., JD, U., . . . Q, M. (2006). Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer chemotherapy and pharmacology, 58(3), 374. https://doi.org/10.1007/s00280-005-0173-6

Chicago Style (17th ed.) Citation

A, Gupta, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, Ross DD, and Mao Q. "Cyclosporin A, Tacrolimus and Sirolimus Are Potent Inhibitors of the Human Breast Cancer Resistance Protein (ABCG2) and Reverse Resistance to Mitoxantrone and Topotecan." Cancer Chemotherapy and Pharmacology 58, no. 3 (2006): 374. https://doi.org/10.1007/s00280-005-0173-6.

MLA (9th ed.) Citation

A, Gupta, et al. "Cyclosporin A, Tacrolimus and Sirolimus Are Potent Inhibitors of the Human Breast Cancer Resistance Protein (ABCG2) and Reverse Resistance to Mitoxantrone and Topotecan." Cancer Chemotherapy and Pharmacology, vol. 58, no. 3, 2006, p. 374, https://doi.org/10.1007/s00280-005-0173-6.